Put your patients in better control.

Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).¹

Dexcom CGM has been shown to reduce median time spent in hypoglycemia by 79% (<60 mg/dL) at night.²

The COMISAIR study demononstrates that Dexcom CGM use–not the insulin delivery method–drives A1C reduction. Both MDI patients and those on pump therapy experience significant glycemic benefits when their insulin regimens are augmented by CGM use.¹